Company news: Glenmark Pharmaceuticals

| Updated on August 30, 2019

Glenmark Pharmaceuticals on Friday said it has received final approval from the USFDA for Pimecrolimus cream, used to treat skin conditions such as eczema. The approved product is a generic version of Elidel cream 1 per cent, of Bausch Health US, LLC. Citing IQVIA sales data, Glenmark said, Elidel cream achieved annual sales of approximately $198.8 million in the 12-month period ended July 2019. The company said its current portfolio consists of 160 products authorised for distribution in the US and 55 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA. Shares of Glenmark Pharma closed at ₹383.90 on the BSE.

Published on August 30, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor